Valeria Frangione

Dr. Valeria Frangione

Preclinical and Clinical Research, IBSA Institut Biochimique (Switzerland), Lugano, Ticino, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2016 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
MCMauro Cervigni
Mauro Cervigni
MSMonica Sommariva
Monica Sommariva
RTRaffaele Tenaglia
Raffaele Tenaglia
DPDaniele Porru
Daniele Porru
EOEdoardo Ostardo
Edoardo Ostardo
GPGiovanni L. Pappagallo
Giovanni L. Pappagallo

1 April 2017 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MRMilko Radicioni
Milko Radicioni
CCChiara Castiglioni
Chiara Castiglioni
AGAndrea Maria Giori
Andrea Maria Giori
ICIrma Cupone
Irma Cupone
Valeria FrangioneValeria Frangione
Valeria Frangione
SRStefano Rovati
Stefano Rovati
Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers Milko Radicioni,1 Chiara Castiglioni,1 Andrea Giori,2 Irma Cupone,3 Valeria Frangione,4 Stefano Rovati4 1CROSS Research S.A., Phase I Unit, Arzo, Switzerland; 2IBSA Farmaceutici Italia, Lodi, Italy; 3Bouty S.p.A., Strada Padana Superiore, Cassina Deâ?? Pecchi, Italy; 4IBSA Institut Biochimique S.A., Pambio-Noranco, Switzerland A new orodispersible film formulation of the phosphodiesterase type 5 inhibitor, sildenafil, has been developed to examine the advantages of an orally disintegrating film formulation and provide an alternative to the current marketed products for the treatment of erectile dysfunction. The pharmacokinetics of the sildenafil 100 mg orodispersible film (IBSA) was compared to that of the conventional marketed 100 mg film-coated tablet (Viagra®) after single-dose administration to 53 healthy male volunteers (aged 18â??51 years) in a randomized, open, two-way crossover bioequivalence study. Each subject received a single oral dose of 100 mg of sildenafil as test or reference formulation administered under fasting conditions at each of the two study periods according to a randomized crossover design. There was a washout interval of â?¥7 days between the two administrations of the investigational medicinal products. Blood samples for pharmacokinetic analysis were collected up to 24 h post-dosing. The primary objective was to compare the rate (peak plasma concentration; Cmax) and extent (area under the curve [AUC] from administration to last observed concentration time; AUC0â??t) of sildenafil absorption after single-dose administration of test and reference. Secondary endpoints were observed to describe the plasma pharmacokinetic profiles of sildenafil and its metabolite N-desmethyl-sildenafil relative bioavailability and safety profile after single-dose administration. The mean sildenafil and N-desmethyl-sildenafil plasma concentrationâ??time profiles up to 24 h after single-dose administration of sildenafil 100 mg orodispersible film and film-coated tablet were nearly superimposable. The bioequivalence test was fully satisfied for sildenafil and N-desmethyl-sildenafil in terms of rate and extent of bioavailability. Adverse events occurred at similar rates for the two formulations and were of mild-to-moderate severity. The results suggest that the new orodispersible film formulation can be used interchangeably with the conventional film-coated formulation. Keywords: sildenafil, pharmacokinetics, bioequivalence, orodispersible film, PDE5 inhibitor, N-desmethyl-sildenafil

4 August 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
Valeria FrangioneValeria Frangione
Valeria Frangione
LMLorenzo Mortara
Lorenzo Mortara
PCPatrizia Castellani
Patrizia Castellani
ABAndrea De Lerma Barbaro
Andrea De Lerma Barbaro
RARoberto Accolla
Roberto Accolla
In our study, we have investigated whether tumors of distinct histological origin can be rejected if expressing CIITA‐driven MHC class II molecules. Moreover, we assessed whether antitumor lymphocytes generated by this approach could be used as an immunotherapeutic tool for established cancers. Stable CIITA‐transfectants of C51colon adenocarcinoma, RENCA renal adenocarcinoma, WEHI‐164 sarcoma as well as TS/A mammary adenocarcinoma were generated. Tumor cells transfectants were injected in vivo, and their growth kinetics and recipient's immune response were analyzed. Tumor rejection and/or retardation of growth was found for the first 3 CIITA‐transfected tumor cell lines and confirmed for TS/A‐CIITA. Animals rejecting CIITA‐transfected tumors acquired specific immunological memory as demonstrated by resistance to challenge with parental tumors. Adoptive cell transfer experiments demonstrated that tumor immunity correlates with the efficient priming of CD4+ T helper cells and the consequent activation of CD8+ T lymphocytes. T cells from TS/A‐vaccinated mice were used in an adoptive immunotherapy model of established tumors. The results showed the cure at early stages and significantly prolonged survival at later stages of tumor progression. Importantly, CD4+ T cells were clearly superior to CD8+ T cells in antitumor protective function. Interestingly, the protective phenotype was associated to both a Th1 and Th2 polarization of the immune effectors. These results establish the general application of our tumor vaccine model and disclose the additional application of this strategy for producing better lymphocyte effectors for adoptive antitumor immunotherapy.

24 April 2009 in International Immunology
Verified
Journal Article
Open access
PDF file
LMLorenzo Mortara
Lorenzo Mortara
Valeria FrangioneValeria Frangione
Valeria Frangione
PCPatrizia Castellani
Patrizia Castellani
ABAndrea De Lerma Barbaro
Andrea De Lerma Barbaro
RARoberto Accolla
Roberto Accolla
In the present study, we investigated the possibility to use irradiated, non-replicating class II transcriptional activator (CIITA)-transfected tumor TS/A cells as a cell-based vaccine. Eighty-three percent of TS/A-CIITA-vaccinated mice were completely protected from tumor growth and the remaining 17% displayed significant reduction of tumor growth. In contrast, only 30% of mice injected with irradiated TS/A parental cells were protected from tumor growth, whereas the remaining 70% of animals remained unprotected. Immunity generated in the TS/A-CIITA-vaccinated mice correlated with an efficient priming of CD4+ T cells and consequent triggering and maintenance of CD8+ CTL effectors, as assessed by adoptive transfer assays. Important qualitative differences were observed between the two cell-based vaccines, as TS/A-CIITA-vaccinated mice developed a CTL response containing a large proportion of anti-gp70 AH1 epitope-specific cells, completely absent in TS/A-vaccinated mice, and a mixed Th1/Th2 type of response as opposed to a Th2 type of response in TS/A-vaccinated mice. Finally, in TS/A-CIITA-vaccinated mice, a statistically significant reduction in the percentage and absolute number of CD4+ CD25+ T regulatory cells as compared with those of untreated mice with growing tumors (P < 0.001) or mice vaccinated with TS/A parental cells were observed. These results let to envisage the use of CIITA-transfected non-replicating tumor cells as a vaccination strategy for prevention and, possibly, adjuvant immunotherapy in human settings.

16 June 2018 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
LLLuca Loprete
Luca Loprete
CLChiara Leuratti
Chiara Leuratti
Valeria FrangioneValeria Frangione
Valeria Frangione
MRMilko Radicioni
Milko Radicioni
Sildenafil was the first selective drug available on the market as oral therapy for erectile dysfunction (ED). A novel sildenafil orodispersible film (ODF) for ED treatment, containing sildenafil citrate, has recently been marketed.

1 April 2007 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Open access
PDF file
Elena BossiElena Bossi
Elena Bossi
ASAndrea Soragna
Andrea Soragna
AMAndreea Miszner
Andreea Miszner
SGStefano Giovannardi
Stefano Giovannardi
Valeria FrangioneValeria Frangione
Valeria Frangione
APAntonio Peres
Antonio Peres
The highly homologous neutral amino acid transporters KAAT1 and CAATCH1, cloned from the midgut epithelium of the Manduca sexta larva, are members of the Na+/Cl−-dependent transporter family. Recent evidence indicates that transporters of this family form constitutive oligomers. CAATCH1 and KAAT1 give rise to specific kinds of current depending on the transported amino acid, cotransported ion, pH, and membrane voltage. Different substrates induce notably distinct transport-associated currents in the two proteins that represent useful tools in structural-functional studies. To determine whether KAAT1 and CAATCH1 form functional oligomers, we have constructed four concatameric proteins for electrophysiological analysis, consisting of one KAAT1 protein covalently linked to another KAAT1 (K-K concatamer) or to CAATCH1 (K-C concatamer) and vice versa (C-C concatamer and C-K concatamer), and eight constructs where the two transporters were linked to yellow or cyan fluorescent protein in the NH2 or COOH terminus, to determine the oligomer formation and the relative distance between the different subunits by fluorescence resonance energy transfer (FRET) analysis. Heterologous expression of the concatenated constructs and coinjection of the original proteins in different proportions allowed us to compare the characteristics of the currents to those of the oocytes expressing only the wild-type proteins. All the constructs were fully active, and their electrophysiological behavior was consistent with the activity as monomeric proteins. However, the FRET studies indicate that these transporters form oligomers in agreement with the LeuTAa atomic structure and confirm that the COOH termini of the adjacent subunits are closer than NH2 termini.